Skip to main content
Top
Published in: Drug Safety 9/2012

01-09-2012 | Current Opinion

A Pathway to Improved Prospective Observational Post-Authorization Safety Studies

Author: Professor Victor A. Kiri

Published in: Drug Safety | Issue 9/2012

Login to get access

Abstract

Randomized controlled trials (RCTs) are the gold standard for assessing the efficacy of drugs but not necessarily so for drug safety where inadequate power to detect either multiple or rare adverse events is a major handicap. Furthermore, the conditions under which drugs are approved for market use are often different from the settings in actual use. Indeed, with their control mechanisms, trials are by design largely inadequate for the identification of potential safety signals, especially of the rare type, hence the value of post-marketing surveillance and risk management plan-based activities.
Today, clinical trials constitute only a part of the research that goes into assessing the safety of drugs. Observational studies, where the investigators merely collect data on treatments received by patients and their health status in routine clinical practice are increasing in uptake because they reflect the real-life utility of drugs, despite the absence of random treatment assignment. Although such studies generally provide less compelling evidence than RCTs, they can be far more useful to drug safety assessment activities than generally acknowledged.
An increasing number of post-authorization safety studies (PASS) within the European Medicines Agency’s jurisdiction are of the observational type —considered perhaps as more appropriate vehicles for exploring and documenting how products perform in the real world. A similar trend is emerging in the US following the FDA Amendments Act of 2007; since early 2010, an increasing number of post-approval commitments mandated by the FDA include observational studies. However, despite this pattern, not much is known about ongoing efforts to address many of the recognized inadequacies associated with existing methodologies and practices currently adopted in observational PASS. This current opinion presents an overview of some of the main challenges we face in prospective observational PASS, mainly from practical experience, and proposes certain steps for improvement.
Literature
1.
3.
go back to reference Papanikolaou PN, Christidi GD, Ioannidis JPA. Com parison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006; 174(5): 635–41PubMedPubMedCentral Papanikolaou PN, Christidi GD, Ioannidis JPA. Com parison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006; 174(5): 635–41PubMedPubMedCentral
4.
go back to reference Ioannidis JP, Lau J. Improving safety reporting from randomized trials. Drug Saf 2002; 25: 77–84PubMed Ioannidis JP, Lau J. Improving safety reporting from randomized trials. Drug Saf 2002; 25: 77–84PubMed
5.
go back to reference Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004; 57: 616–21PubMedPubMedCentral Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004; 57: 616–21PubMedPubMedCentral
6.
go back to reference Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878–86PubMed Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878–86PubMed
7.
go back to reference Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887–92PubMedPubMedCentral Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887–92PubMedPubMedCentral
8.
go back to reference Vandenbroucke JP. When are observational studies as credible as randomized trials? Lancet 2004; 363: 1728–31PubMed Vandenbroucke JP. When are observational studies as credible as randomized trials? Lancet 2004; 363: 1728–31PubMed
9.
go back to reference Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983; 2: 267–71PubMed Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983; 2: 267–71PubMed
10.
go back to reference Grootendorst DC, Jager KJ, Zoccali C, et al. Observa tional studies are complementary to randomized controlled trials. Nephron Clin Pract 2010; 114: c173–7PubMed Grootendorst DC, Jager KJ, Zoccali C, et al. Observa tional studies are complementary to randomized controlled trials. Nephron Clin Pract 2010; 114: c173–7PubMed
11.
12.
go back to reference Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071–3PubMed Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071–3PubMed
13.
go back to reference Zhao SZ, Burke TA, Whelton A, et al. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care 2002 Oct; 8 (15 Suppl.): S414–27PubMed Zhao SZ, Burke TA, Whelton A, et al. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care 2002 Oct; 8 (15 Suppl.): S414–27PubMed
14.
go back to reference Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004 May 4; 109(17): 2068–73PubMed Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004 May 4; 109(17): 2068–73PubMed
15.
go back to reference Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of non-fatal myocardial infarction. Ann Intern Med 2005 Feb 1; 142(3): 157–64PubMed Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of non-fatal myocardial infarction. Ann Intern Med 2005 Feb 1; 142(3): 157–64PubMed
16.
go back to reference Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005 Feb 5-11; 365(9458): 475–81PubMed Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005 Feb 5-11; 365(9458): 475–81PubMed
17.
go back to reference Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005 May 9; 165(9): 978–84PubMed Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005 May 9; 165(9): 978–84PubMed
18.
go back to reference Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 2006; 29(7): 621–32PubMed Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 2006; 29(7): 621–32PubMed
19.
go back to reference Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective non-steroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006 Jun 27; 113(25): 2906–13PubMed Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective non-steroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006 Jun 27; 113(25): 2906–13PubMed
20.
go back to reference Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006 Mar; 98(3): 266–74PubMed Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006 Mar; 98(3): 266–74PubMed
21.
go back to reference Huang WF, Hsiao FY, Tsai YW, et al. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf 2006; 29(3): 261–72PubMed Huang WF, Hsiao FY, Tsai YW, et al. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf 2006; 29(3): 261–72PubMed
22.
go back to reference Rahme E, Watson DJ, Kong SX, et al. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitaliz ation for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2007 May; 16(5): 493–503PubMed Rahme E, Watson DJ, Kong SX, et al. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitaliz ation for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2007 May; 16(5): 493–503PubMed
23.
go back to reference Cunnington M, Webb D, Qizilbash N, et al. Risk of ischaemic cardiovascular events from selective cyclooxy genase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf 2008 Jun; 17(6): 601–8PubMed Cunnington M, Webb D, Qizilbash N, et al. Risk of ischaemic cardiovascular events from selective cyclooxy genase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf 2008 Jun; 17(6): 601–8PubMed
24.
go back to reference Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353–65PubMed Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353–65PubMed
25.
go back to reference Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high transfusion- risk cardiac surgery. Trans fusion 2006; 46: 327–38 Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high transfusion- risk cardiac surgery. Trans fusion 2006; 46: 327–38
28.
go back to reference Twachtman G. FDA’s post-market pharmacoepidemiologic study guidance is 3 years away. Pink Sheet 2008; 70(019): 21 Twachtman G. FDA’s post-market pharmacoepidemiologic study guidance is 3 years away. Pink Sheet 2008; 70(019): 21
31.
go back to reference Skegg DCG. Pitfalls of pharmacoepidemiology: oral contraceptive studies show a need for caution with databases. BMJ 2000; 321: 1171–2PubMedPubMedCentral Skegg DCG. Pitfalls of pharmacoepidemiology: oral contraceptive studies show a need for caution with databases. BMJ 2000; 321: 1171–2PubMedPubMedCentral
33.
go back to reference Farmer RDT, Williams TJ, Simpson EL, et al. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. BMJ 2000; 321:477–9PubMedPubMedCentral Farmer RDT, Williams TJ, Simpson EL, et al. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. BMJ 2000; 321:477–9PubMedPubMedCentral
35.
go back to reference Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboem bolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93PubMed Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboem bolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93PubMed
36.
go back to reference Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998; 57: 169–81PubMed Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998; 57: 169–81PubMed
37.
go back to reference Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous throm-boembolic disorders: an international case-control study. BMJ 1996; 312: 83–8PubMedPubMedCentral Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous throm-boembolic disorders: an international case-control study. BMJ 1996; 312: 83–8PubMedPubMedCentral
38.
go back to reference Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestogens: role of bias in observa tional research. Contraception 1996; 54: 5–13PubMed Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestogens: role of bias in observa tional research. Contraception 1996; 54: 5–13PubMed
39.
go back to reference Farley TMM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999; 5:721–35PubMed Farley TMM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999; 5:721–35PubMed
40.
go back to reference Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboem bolism. Contraception 1997; 56: 141–6PubMed Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboem bolism. Contraception 1997; 56: 141–6PubMed
41.
go back to reference Lewis MA, MacRae KD, Kuhl-Habich D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493–9PubMed Lewis MA, MacRae KD, Kuhl-Habich D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493–9PubMed
42.
go back to reference Suissa S, Spitzer WO, Rainville B, et al. Recurrent use of newer oral contraceptives and the risk of venous throm boembolism. Hum Reprod 2000; 15: 817–21PubMed Suissa S, Spitzer WO, Rainville B, et al. Recurrent use of newer oral contraceptives and the risk of venous throm boembolism. Hum Reprod 2000; 15: 817–21PubMed
43.
go back to reference Farmer RDT, Lawrenson RA, Todd J-C, et al. Oral contraceptives and venous thromboembolic disease: analyses of the UK General Practice Research Database and the MediPlus Database. Hum Reprod Update 1999; 5: 688–706PubMed Farmer RDT, Lawrenson RA, Todd J-C, et al. Oral contraceptives and venous thromboembolic disease: analyses of the UK General Practice Research Database and the MediPlus Database. Hum Reprod Update 1999; 5: 688–706PubMed
44.
go back to reference Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79–83PubMed Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79–83PubMed
45.
go back to reference Vandenbroucke JP, Helmerhorst FM, Rosendaal FR. Competing interests and controversy about third generation oral contraceptives. BMJ 2000; 320: 381–2PubMedPubMedCentral Vandenbroucke JP, Helmerhorst FM, Rosendaal FR. Competing interests and controversy about third generation oral contraceptives. BMJ 2000; 320: 381–2PubMedPubMedCentral
46.
go back to reference Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190–5PubMedPubMedCentral Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190–5PubMedPubMedCentral
47.
go back to reference Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168(1): 49–53PubMed Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168(1): 49–53PubMed
48.
go back to reference Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 23: 391–5PubMed Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 23: 391–5PubMed
49.
go back to reference Kiri VA, Vestbo J, Pride NB, et al. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 24: 190–1PubMed Kiri VA, Vestbo J, Pride NB, et al. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 24: 190–1PubMed
50.
go back to reference Kiri VA, Pride NB, Soriano JB, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172: 460–4PubMed Kiri VA, Pride NB, Soriano JB, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172: 460–4PubMed
51.
go back to reference Suissa S. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias [letter]. Am J Respir Crit Care Med 2006; 173: 464PubMed Suissa S. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias [letter]. Am J Respir Crit Care Med 2006; 173: 464PubMed
52.
go back to reference Kiri VA, Pride NB, Soriano JB, et al. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias [reply]. Am J Respir Crit Care Med 2006; 173: 464a–465 Kiri VA, Pride NB, Soriano JB, et al. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias [reply]. Am J Respir Crit Care Med 2006; 173: 464a–465
53.
go back to reference Regulation (EU) No 1235/2010 of the European parliament and of the council, amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the au thorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products [online]. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf [Accessed 2012 Jul 16] Regulation (EU) No 1235/2010 of the European parliament and of the council, amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the au thorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products [online]. Available from URL: http://​ec.​europa.​eu/​health/​files/​eudralex/​vol-1/​reg_​2010_​1235/​reg_​2010_​1235_​en.​pdf [Accessed 2012 Jul 16]
54.
go back to reference Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Evaluation of post-authorization afety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Saf 2009; 32(12): 1175–87PubMed Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Evaluation of post-authorization afety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Saf 2009; 32(12): 1175–87PubMed
56.
go back to reference Greenland A. The effect of misclassification in the presence of covariates. Am J Epidemiol 1980; 112(4): 564–9PubMed Greenland A. The effect of misclassification in the presence of covariates. Am J Epidemiol 1980; 112(4): 564–9PubMed
57.
go back to reference Soriano JB, Maier WC, Visick G, et al. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001; 17: 1075–80PubMed Soriano JB, Maier WC, Visick G, et al. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001; 17: 1075–80PubMed
58.
go back to reference Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care data files. Stat Med 1995; 14: 2627–43PubMed Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care data files. Stat Med 1995; 14: 2627–43PubMed
59.
go back to reference Lanes SF, de Luise C. Bias due to false-positive diagnoses in an automated health insurance claims database. Drug Saf 2006; 29(11): 1069–75PubMed Lanes SF, de Luise C. Bias due to false-positive diagnoses in an automated health insurance claims database. Drug Saf 2006; 29(11): 1069–75PubMed
60.
go back to reference Bross I. Misclassification in 2×2 tables. Biometrics 1954; 10: 478–86 Bross I. Misclassification in 2×2 tables. Biometrics 1954; 10: 478–86
61.
go back to reference Bueil P, Dunn JE. The dilution effect of misclassification. Am J Public Health 1964; 54: 598–602 Bueil P, Dunn JE. The dilution effect of misclassification. Am J Public Health 1964; 54: 598–602
62.
go back to reference Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977; 105: 488–95PubMed Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977; 105: 488–95PubMed
63.
go back to reference Keys A, Kihlberg JK. Effects of misclassification on estimated relative prevalence of a characteristic. Part 1: two populations infallibly distinguished. Part II: errors in two variables. Am J Public Health 1963; 53: 1656–65 Keys A, Kihlberg JK. Effects of misclassification on estimated relative prevalence of a characteristic. Part 1: two populations infallibly distinguished. Part II: errors in two variables. Am J Public Health 1963; 53: 1656–65
64.
go back to reference Newell DJ. Errors in the interpretation of errors in epidemiology. Am J Public Health 1962; 52: 1925–8 Newell DJ. Errors in the interpretation of errors in epidemiology. Am J Public Health 1962; 52: 1925–8
65.
go back to reference Gullen WH, Bearmnn JE, Johnson EA. Effect of misclassification in epidemiologic studies. Public Health Rep 1968; 83: 914–8PubMedPubMedCentral Gullen WH, Bearmnn JE, Johnson EA. Effect of misclassification in epidemiologic studies. Public Health Rep 1968; 83: 914–8PubMedPubMedCentral
66.
go back to reference Stampfer MJ. ITT for observational data: worst of both worlds? Epidemiology 1995; 6: 248–53 Stampfer MJ. ITT for observational data: worst of both worlds? Epidemiology 1995; 6: 248–53
67.
go back to reference Miettenen OS, Caro JJ. Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. J Clin Epidemiol 1989; 42(4): 325–31 Miettenen OS, Caro JJ. Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. J Clin Epidemiol 1989; 42(4): 325–31
68.
go back to reference Guess HA. Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time. J Clin Epidemiol 1989; 42(12): 1179–84PubMed Guess HA. Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time. J Clin Epidemiol 1989; 42(12): 1179–84PubMed
69.
go back to reference Kiri VA, McKenzie G. How real is intention-to-treat (ITT) analysis in non-interventional PASS? We can do better. Curr Drug Saf 2009; 4(2): 137–42PubMed Kiri VA, McKenzie G. How real is intention-to-treat (ITT) analysis in non-interventional PASS? We can do better. Curr Drug Saf 2009; 4(2): 137–42PubMed
70.
go back to reference Kiri VA, Oyee J. Assessing the time-dependency nature of comorbidity influence in COPD [abstract]. Pharmacoepidemiol Drug Saf 2006; 15 Suppl. 2: S8 Kiri VA, Oyee J. Assessing the time-dependency nature of comorbidity influence in COPD [abstract]. Pharmacoepidemiol Drug Saf 2006; 15 Suppl. 2: S8
71.
go back to reference Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMed Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMed
72.
go back to reference Kiri VA, Muellerova H, Visick G, et al. A novel metho dology for measuring the influence of comorbidity in disease outcome studies [abstract]. Pharmacoepidemiol Drug Saf 2005; 14 Suppl. 2: S135 Kiri VA, Muellerova H, Visick G, et al. A novel metho dology for measuring the influence of comorbidity in disease outcome studies [abstract]. Pharmacoepidemiol Drug Saf 2005; 14 Suppl. 2: S135
73.
go back to reference Kiri VA, Muellerova H, Visick G, et al. Assessing the multivariate structure and influence of comorbidity in COPD [abstract]. Eur Respir J 2005; 26 Suppl. 49: A470s Kiri VA, Muellerova H, Visick G, et al. Assessing the multivariate structure and influence of comorbidity in COPD [abstract]. Eur Respir J 2005; 26 Suppl. 49: A470s
74.
go back to reference Horwitz RI, Feinstein AR. The problem of protopathic bias in case-control studies. Am J Med 1980 Feb; 68: 255–8PubMed Horwitz RI, Feinstein AR. The problem of protopathic bias in case-control studies. Am J Med 1980 Feb; 68: 255–8PubMed
75.
go back to reference Salas M, Hofman A, Stricker BH. Confounding by in dication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149: 981–3PubMed Salas M, Hofman A, Stricker BH. Confounding by in dication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149: 981–3PubMed
76.
go back to reference Clayton D, Hills M. Statistical methods in epidemiology. Oxford: Oxford University Press, 1993: 309 Clayton D, Hills M. Statistical methods in epidemiology. Oxford: Oxford University Press, 1993: 309
77.
go back to reference Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1998: 87 Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1998: 87
78.
go back to reference Strom BL, ed. Pharmacoepidemiology. 4th ed. West Sussex: John Wiley & Sons Ltd, 2005 Strom BL, ed. Pharmacoepidemiology. 4th ed. West Sussex: John Wiley & Sons Ltd, 2005
79.
go back to reference Tamim H, Tahami Monfared AA, Le Lorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007; 16(3): 250–8PubMed Tamim H, Tahami Monfared AA, Le Lorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007; 16(3): 250–8PubMed
80.
go back to reference Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for casual effects. Biometrika 1983; 70: 41–55 Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for casual effects. Biometrika 1983; 70: 41–55
81.
go back to reference Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1994; 79(387): 516–24 Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1994; 79(387): 516–24
82.
go back to reference D’Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265–81PubMed D’Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265–81PubMed
83.
go back to reference Stürmer T, Schneeweiss S, Rothman KJ, et al. Performance of propensity score calibration: a simulation study. Am J Epidemiol 2007; 165(10): 1110–8PubMed Stürmer T, Schneeweiss S, Rothman KJ, et al. Performance of propensity score calibration: a simulation study. Am J Epidemiol 2007; 165(10): 1110–8PubMed
84.
go back to reference Stürmer T, Schneeweiss S, Rothman KJ, et al. Propensity score calibration and its alternatives. Am J Epidemiol 2007; 165(10): 1122–3PubMed Stürmer T, Schneeweiss S, Rothman KJ, et al. Propensity score calibration and its alternatives. Am J Epidemiol 2007; 165(10): 1122–3PubMed
85.
go back to reference Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000; 29: 722–9PubMed Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000; 29: 722–9PubMed
86.
go back to reference Stürmer T, Schneeweiss S, Avorn J, et al. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 2005; 162: 279–89PubMed Stürmer T, Schneeweiss S, Avorn J, et al. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 2005; 162: 279–89PubMed
87.
go back to reference Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009; 18(1): 67–80PubMed Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009; 18(1): 67–80PubMed
88.
go back to reference Heckman JJ, Vytlacil EJ. Local instrumental variables and latent variable models for identifying and bounding treatment effects. Proc Natl Acad Sci U S A 1999; 96: 4730–4PubMedPubMedCentral Heckman JJ, Vytlacil EJ. Local instrumental variables and latent variable models for identifying and bounding treatment effects. Proc Natl Acad Sci U S A 1999; 96: 4730–4PubMedPubMedCentral
89.
go back to reference Crown WH, Obenchain RL, Englehart L, et al. The appli cation of sample selection models to outcomes research: the case of evaluating the effects of antidepressants ther apy on resource utilization. Stat Med 1998; 17: 1943–58PubMed Crown WH, Obenchain RL, Englehart L, et al. The appli cation of sample selection models to outcomes research: the case of evaluating the effects of antidepressants ther apy on resource utilization. Stat Med 1998; 17: 1943–58PubMed
90.
go back to reference Shelton BJ, Gilbery GH, Lu Z, et al. Comparing longitudinal binary outcomes in an observational oral health study. Stat Med 2003; 22(12): 2057–7PubMed Shelton BJ, Gilbery GH, Lu Z, et al. Comparing longitudinal binary outcomes in an observational oral health study. Stat Med 2003; 22(12): 2057–7PubMed
92.
go back to reference ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17: 200–8 ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17: 200–8
93.
go back to reference Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user’s guide. (prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under contract no. HHSA29020050035I TO1.) AHRQ Publication No. 07-EHC001-1. Rockville (MD): Agency for Healthcare Research and Quality, 2007 Apr Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user’s guide. (prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under contract no. HHSA29020050035I TO1.) AHRQ Publication No. 07-EHC001-1. Rockville (MD): Agency for Healthcare Research and Quality, 2007 Apr
94.
go back to reference Dreyer NA, Schneeweiss S, McNeil BJ, et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Man Care 2010; 16(6): 21–4 Dreyer NA, Schneeweiss S, McNeil BJ, et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Man Care 2010; 16(6): 21–4
95.
go back to reference Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report — Part I. Value Health 2009: 1044-72 [online]. Available from URL: http://www.is-por.org/taskforces/documents/RDPartI.pdf [Accessed 2012 Jul 20] Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report — Part I. Value Health 2009: 1044-72 [online]. Available from URL: http://​www.​is-por.​org/​taskforces/​documents/​RDPartI.​pdf [Accessed 2012 Jul 20]
96.
go back to reference Vandenbroucke JP, von Elm E, Altman DG. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007; 18(6): 805–35PubMed Vandenbroucke JP, von Elm E, Altman DG. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007; 18(6): 805–35PubMed
98.
go back to reference European Federation of Pharmaceutical Industries and Associations. EFPIA code on the promotion of prescription only medicines to, and interactions with, healthcare professionals [online]. Available from URL: http://www.efpia.eu/code-conduct [Accessed 2012 Jul 20] European Federation of Pharmaceutical Industries and Associations. EFPIA code on the promotion of prescription only medicines to, and interactions with, healthcare professionals [online]. Available from URL: http://​www.​efpia.​eu/​code-conduct [Accessed 2012 Jul 20]
101.
go back to reference Tantsyura V, Grimes I, Mitchel J, et al. Risk-based source data verification: pros and cons. Drug Inf J 2010; 44: 745–56 Tantsyura V, Grimes I, Mitchel J, et al. Risk-based source data verification: pros and cons. Drug Inf J 2010; 44: 745–56
102.
go back to reference Hughes MD, Williams PL. Challenges in using observa tional studies to evaluate adverse effects of treatment. N Engl J Med 2007; 356(17): 1705–7PubMed Hughes MD, Williams PL. Challenges in using observa tional studies to evaluate adverse effects of treatment. N Engl J Med 2007; 356(17): 1705–7PubMed
103.
go back to reference Smeeth L, Douglas I, Hubbard R. Commentary: we still need observational studies of drugs — they just need to be better. Int J Epidemiol 2006; 35: 1310–1PubMed Smeeth L, Douglas I, Hubbard R. Commentary: we still need observational studies of drugs — they just need to be better. Int J Epidemiol 2006; 35: 1310–1PubMed
Metadata
Title
A Pathway to Improved Prospective Observational Post-Authorization Safety Studies
Author
Professor Victor A. Kiri
Publication date
01-09-2012
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 9/2012
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/BF03261968

Other articles of this Issue 9/2012

Drug Safety 9/2012 Go to the issue

Original Research Article

Drug Interactions in Dying Patients

Original Research Article

Drug Fever